NCT02899286View on ClinicalTrials.gov

Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE2UnknownINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

March 31, 2020

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

PEG-BCT-100

PEGylated recombinant human arginase

Trial Locations (1)

Unknown

The University of Hong Kong, Queen Mary Hospital, Hong Kong

Sponsors
All Listed Sponsors
lead

Bio-Cancer Treatment International Limited

INDUSTRY

NCT02899286 - Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter